Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of CK0802 for treatment of COVID-19

Trial Profile

A phase 1/2 study of CK0802 for treatment of COVID-19

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2020

At a glance

  • Drugs CK 0802 (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Mar 2020 New trial record
    • 17 Mar 2020 According to a Cellenkos media release, the company has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority (BARDA) to start this study.

Trial Overview

Purpose

This is a phase 1/2 study of CK0802 for treatment of COVID-19 mediated acute respiratory distress syndrome (CoV-ARDS).

Diseases Treated

Indication Qualifiers Patient Segments
Adult respiratory distress syndrome treatment -
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex not stated

Trial Details

Organisations

  • Affiliations Cellenkos

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I/II
  • Location Unknown
  • Focus Adverse reactions; Therapeutic Use

Interventions

Drugs Route Formulation
CK 0802Primary Drug Intravenous
-

CK0802

Trial History

Event Date Event Type Comment
18 Mar 2020 New trial record New trial record Updated 18 Mar 2020
17 Mar 2020 Other trial event According to a Cellenkos media release, the company has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority (BARDA) to start this study. Updated 18 Mar 2020

References

  1. Cellenkos. Cellenkos Inc. Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS). Media-Rel 2020;.

    Media Release
Back to top